SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 165764.
  • 2
    Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000; 10: 7393.
  • 3
    McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25: 134151.
  • 4
    Couturier O, Faivre-Chauvet A, Filippovich IV, Thedrez P, Sai-Maurel C, Bardies M, et al. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res 1999; 5(10 Suppl ): 3165s3170s.
  • 5
    Clement C, Vooys WC, Klein B, Wijdeness J. B-B2 and B-B4, two new Moabs against secreting plasma cells. In: Schlossman S, editor. Proceedings of the fifth international workshop and conference on human leukocyte differentiation antigens, Boston; 1995:174.
  • 6
    Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 31823.
  • 7
    Vooijs WC, Post J, Wijdenes J, Schuurman HJ, Bolognesi A, Polito L, et al. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother 1996; 42: 31928.
  • 8
    Dore JM, Morard F, Vita N, Wijdenes J. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies. Febs Lett 1998; 426: 6770.
  • 9
    Burton J, Mishina D, Cardillo T, Lew K, Rubin A, Goldenberg DM, et al. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res 1999; 5(10 Suppl ): 3065s3072s.
  • 10
    Treon SP, Maimonis P, Bua D, Bua D, Young G, Raje N, Mollick J, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96: 314753.
  • 11
    Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93: 128798.
  • 12
    Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995; 1241: 40723.
  • 13
    Major PP, Dion AS, Williams CJ, Mattes MJ, Wang T, Rosenthall L. Breast tumor radioimmunodetection with a 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen. Cancer Res 1990; 50(3 Suppl ): 927s931s.
  • 14
    Brechbiel MW, Gansow OA, Atcher RW, et al. Synthesis of 1-(p-Isothiocyanatobenzyl) Derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg Chem 1986; 25: 277281.
  • 15
    Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW, Apostolidis C, Molinet R. Cytotoxicity of 213Bi- and 225Ac-immunoconjugates. Nucl Med Commun 1995; 16: 46876.
  • 16
    Salacinski PR, McLean C, Sykes JE, Clement JV, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 1981; 117: 13646.
  • 17
    Preijers FW, Tax WJ, De Witte T, Janssen A, vd Heijden H, Vidal H, et al. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins. Br J Haematol 1988; 70: 28994.
  • 18
    Jungerman JA, Yu KH, Zanelli CI. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. Int J Appl Radiat Isot 1984; 35: 8838.
  • 19
    Wheldon TE, O'Donoghue JA, Barrett A, Michalowski AS. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991; 21: 919.
  • 20
    Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 14907.
  • 21
    O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, et al. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm 1998; 13: 35161.
  • 22
    Little J. Delayed iniation of DNA synthesis in irradiated human diploid cells. Nature 1968; 218: 10645.
  • 23
    Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7: 253943.
  • 24
    Mazars GR, Portier M, Zhang XG, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 10158. [Published erratum appears in Oncogene 1993;8:1107.]
  • 25
    Nagasawa H, Keng P, Harley R, Dahlberg W, Little JB. Relationship between gamma-ray-induced G2/M delay and cellular radiosensitivity. Int J Radiat Biol 1994; 66: 3739.
  • 26
    Skwarchuk MW, Wouters BG, Skarsgard LD. Substructure in the radiation survival response at low dose: asynchronous and partially synchronized V79-WNRE cells. Int J Radiat Biol 1993; 64: 60112.
  • 27
    Ning S, Knox SJ. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat Res 1999; 151: 65969.
  • 28
    Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 45965.
  • 29
    Jurcic JG, Sgouros G, Ballangrud A, Ma D, Hamacher K, Geerlings MW, Humm JL, Brechbiel RM, Apostolidis C, Larson SM, Scheinberg DA. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33). American Society of Clinical Oncology, 1999:Abstract 22.
  • 30
    Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 4849.
  • 31
    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 156571. [Published erratum appears in N Engl J Med 2000;342:364.]
  • 32
    Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335: 917.